Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Saved in:
| Title: | Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. |
|---|---|
| Authors: | Pascual J; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Lim JSJ; National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore., Macpherson IR; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Armstrong AC; Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom., Ring A; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom., Okines AFC; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom., Cutts RJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Herrera-Abreu MT; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Garcia-Murillas I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Pearson A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Hrebien S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Gevensleben H; University Hospital Bonn, Bonn, Germany., Proszek PZ; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Hubank M; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Hills M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom., King J; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Parmar M; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Prout T; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Finneran L; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Malia J; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Swales KE; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Ruddle R; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Raynaud FI; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Turner A; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Hall E; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Lopez JS; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Turner NC; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. nick.turner@icr.ac.uk.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. |
| Source: | Cancer discovery [Cancer Discov] 2021 Jan; Vol. 11 (1), pp. 92-107. Date of Electronic Publication: 2020 Sep 21. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32958578 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pascual+J%22">Pascual J</searchLink>; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lim+JSJ%22">Lim JSJ</searchLink>; National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore.<br /><searchLink fieldCode="AU" term="%22Macpherson+IR%22">Macpherson IR</searchLink>; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Armstrong+AC%22">Armstrong AC</searchLink>; Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ring+A%22">Ring A</searchLink>; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Okines+AFC%22">Okines AFC</searchLink>; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Cutts+RJ%22">Cutts RJ</searchLink>; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Herrera-Abreu+MT%22">Herrera-Abreu MT</searchLink>; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Garcia-Murillas+I%22">Garcia-Murillas I</searchLink>; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pearson+A%22">Pearson A</searchLink>; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hrebien+S%22">Hrebien S</searchLink>; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gevensleben+H%22">Gevensleben H</searchLink>; University Hospital Bonn, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Proszek+PZ%22">Proszek PZ</searchLink>; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hubank+M%22">Hubank M</searchLink>; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hills+M%22">Hills M</searchLink>; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22King+J%22">King J</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Parmar+M%22">Parmar M</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Prout+T%22">Prout T</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Finneran+L%22">Finneran L</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Malia+J%22">Malia J</searchLink>; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Swales+KE%22">Swales KE</searchLink>; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ruddle+R%22">Ruddle R</searchLink>; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Raynaud+FI%22">Raynaud FI</searchLink>; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Turner+A%22">Turner A</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hall+E%22">Hall E</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lopez+JS%22">Lopez JS</searchLink>; Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Turner+NC%22">Turner NC</searchLink>; Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. nick.turner@icr.ac.uk.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101561693%22">Cancer discovery</searchLink> [Cancer Discov] 2021 Jan; Vol. 11 (1), pp. 92-107. <i>Date of Electronic Publication: </i>2020 Sep 21. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101561693 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2159-8290 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221598274%22">21598274 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Discov <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32958578 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/2159-8290.CD-20-0553 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 92 Titles: – TitleFull: Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pascual J – PersonEntity: Name: NameFull: Lim JSJ – PersonEntity: Name: NameFull: Macpherson IR – PersonEntity: Name: NameFull: Armstrong AC – PersonEntity: Name: NameFull: Ring A – PersonEntity: Name: NameFull: Okines AFC – PersonEntity: Name: NameFull: Cutts RJ – PersonEntity: Name: NameFull: Herrera-Abreu MT – PersonEntity: Name: NameFull: Garcia-Murillas I – PersonEntity: Name: NameFull: Pearson A – PersonEntity: Name: NameFull: Hrebien S – PersonEntity: Name: NameFull: Gevensleben H – PersonEntity: Name: NameFull: Proszek PZ – PersonEntity: Name: NameFull: Hubank M – PersonEntity: Name: NameFull: Hills M – PersonEntity: Name: NameFull: King J – PersonEntity: Name: NameFull: Parmar M – PersonEntity: Name: NameFull: Prout T – PersonEntity: Name: NameFull: Finneran L – PersonEntity: Name: NameFull: Malia J – PersonEntity: Name: NameFull: Swales KE – PersonEntity: Name: NameFull: Ruddle R – PersonEntity: Name: NameFull: Raynaud FI – PersonEntity: Name: NameFull: Turner A – PersonEntity: Name: NameFull: Hall E – PersonEntity: Name: NameFull: Yap TA – PersonEntity: Name: NameFull: Lopez JS – PersonEntity: Name: NameFull: Turner NC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2021 Jan Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 2159-8290 Numbering: – Type: volume Value: 11 – Type: issue Value: 1 Titles: – TitleFull: Cancer discovery Type: main |
| ResultId | 1 |
